



WEDNESDAY 8th MAY 2013 COMMENCING 9.30 AM

(UNTIL 4.00 PM APPROX)

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

- | | Enclosure |
|--|-----------------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Chairman's report (verbal update) | |
| 5. Minutes of previous meeting | 1/AWMSG/0513 |
| 6. Appraisal 1 – Full submission
Acclidinium bromide (Eklira[®]Genuair[®]) for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease | 2/AWMSG/0513
Appendices |
| 7. Appraisal 2 – Full submission
Ferumoxytol (Rienso[®]) for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease. The diagnosis of iron deficiency must be based on appropriate laboratory tests | 3/AWMSG/0513
Appendices |
| 8. Appraisal 3 – Full submission
Ingenol mebutate (Picato[®]) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults | 4/AWMSG/0513
Appendices |
| 9. Appraisal 4 – Limited submission
Linagliptin/metformin (Jentaduo[®]) for the treatment of adult patients with type 2 diabetes mellitus: <ul style="list-style-type: none">– as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin;– in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea | 5/AWMSG/0513
Appendices |
| 10. Appraisal 5 – Limited submission
Darunavir (Prezista[®]) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight | 6/AWMSG/0513
Appendices |

**Proceedings held in public will close and, to protect commercial confidentiality,
Appraisal 6 & 7 will be conducted in private.
The final appraisal recommendation will be announced in public.**

11. **Appraisal 6 – Full submission/Wales Patient Access Scheme
Ivacaftor (Kalydeco[®])** for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the CFTR gene **7/AWMSG/0513
Appendices**
12. **Appraisal 7 – Full submission/Wales Patient Access Scheme
Perampanel (Fycompa[®])** for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older **8/AWMSG/0513
Appendices**
13. **AWPAG update (draft minutes of March 2013 meeting)** **9/AWMSG/0513**
14. **Recommendations for Homecare Services** **10/AWMSG/0513**
15. **Dyspepsia and Proton Pump Inhibitor Educational Pack** **11/AWMSG/0513**
16. **Common Ailments Service Formulary** **12/AWMSG/0513**
17. **Quarterly National Indicator report** **13/AWMSG/0513**
18. **Date of next meeting:
Wednesday 12th June in Abergavenny**